Knowledge Centre

Getting diagnosed with PMOS (PCOS), should not take years. Yet many people are dismissed, told their symptoms are normal, or given the pill without being told what is driving their irregular periods, acne, excess hair growth or fertility concerns. PMOS is diagnosed using the Rotterdam criteria. This means you need to meet at least 2 out of 3 criteria: irregular or absent periods, signs of high androgens, and/or polycystic ovarian morphology on ultrasound or AMH testing. Other conditions, such as thyroid disorders and raised prolactin, should also be ruled out. This guide explains the tests used to diagnose PMOS, what the criteria mean, whether you need an ultrasound, and what to do if you are not getting clear answers. Quick facts: What tests are used to diagnose PMOS (PCOS)? There is no single test that can diagnose polyendocrine metabolic ovarian syndrome, or PMOS. Instead, diagnosis is usually based on a combination of your symptoms, menstrual cycle pattern, hormone levels, metabolic health markers and, in some cases, an ultrasound scan. Your doctor may recommend a combination of the following assessments. Medical history and symptom assessment The first step is usually a detailed conversation about your symptoms and health history. This may include questions about: This helps build a clearer picture of whether your symptoms fit with PMOS and whether other conditions need to be ruled out. Physical examination A clinician may also look for physical signs that can be associated with PMOS. These may include acne, excess facial or body hair, scalp hair thinning, skin tags or darker velvety patches of skin, which can sometimes be linked to insulin resistance. This helps identify patterns that may guide further testing. Blood tests for PMOS (PCOS) Blood tests are often used to check hormone levels, assess metabolic health and rule out other conditions that can cause similar symptoms. These may include: These tests help identify whether PMOS is likely, how it may be affecting your body, and what kind of support may be most appropriate. Pelvic ultrasound scan for PMOS (PCOS) A pelvic ultrasound may be recommended to look at the ovaries and uterus. This can help assess whether the ovaries have a polycystic appearance, meaning they contain a higher number of small follicles. A transvaginal ultrasound is often used because it provides a clearer view of the ovaries. This involves placing a slim ultrasound probe into the vagina, which uses sound waves to create images on a screen. However, having polycystic-looking ovaries alone is not enough to diagnose PMOS. Some people have polycystic ovaries without symptoms, and some people with PMOS may not have obvious changes on ultrasound. Pelvic examination In some cases, a pelvic examination may be offered to check for abnormalities or signs of other reproductive health conditions. This is not always needed for a PMOS diagnosis, but it may be useful if you have symptoms such as pelvic pain, abnormal bleeding or pain during sex. Testing does more than confirm a diagnosis. It can help rule out other causes of irregular periods, acne, excess hair growth or difficulty conceiving, and it can identify whether PMOS is affecting ovulation, hormone balance or metabolic health. That means your care can be tailored to what is actually happening in your body, whether that involves cycle support, fertility planning, skin and hair treatment, metabolic health support or longer-term monitoring. How is PMOS/PCOS diagnosed? PMOS is diagnosed using the Rotterdam criteria, the internationally recognised diagnostic framework, most recently updated in the 2023 International Evidence-Based PCOS Guidelines. To receive a diagnosis, you must meet at least 2 of the following 3 criteria. You do not need all three. Criterion 1: Irregular or absent menstrual cycles This criterion reflects the disruption to ovulation that is central to PMOS. When elevated androgens interfere with follicle development, ovulation doesn’t happen reliably, and without ovulation, the regular hormonal cycle that produces a period is disrupted. What counts as irregular?  A single late or missing period doesn’t meet this criterion, it needs to be a consistent pattern, not an occasional variation. Criterion 2: Clinical or biochemical hyperandrogenism (elevated androgens) This criterion reflects the androgen excess that is the hormonal driver of many PMOS symptoms. It can be met in two ways, through physical symptoms, or through blood test results, either is sufficient. Clinical hyperandrogenism means physical signs of elevated androgen activity: Biochemical hyperandrogenism means elevated androgens on a blood test including high testosterone and DHEAS. SHBG is a protein that binds to testosterone and reduces its biological activity. In PMOS, SHBG is often low, meaning more testosterone is free and active. This is why a PMOS-focused blood panel should always include SHBG alongside testosterone, not testosterone in isolation. Hormonal contraception can raise SHBG significantly, which suppresses testosterone and can mask androgen excess entirely. If you’re on or have recently stopped the pill, your androgen levels may not reflect your true baseline for several months. Ideally, androgens should be tested at least 3 full cycles after stopping hormonal contraception for the most accurate picture. Criterion 3: Polycystic ovarian morphology (PCOM) This criterion refers to evidence of the characteristic ovarian appearance associated with PMOS, a high number of follicles that haven’t been able to progress to ovulation. It can now be assessed in two ways: Transvaginal ultrasound (TVUS) A pelvic ultrasound scan counts the number of follicles visible in each ovary. The scan should ideally be performed in the early follicular phase, days 1-7 of the menstrual cycle, when follicles are at their most clearly countable.  AMH blood test This is the significant change introduced in the updated 2023 guidelines. AMH (anti-Müllerian hormone) is a hormone made by the follicles themselves. In PMOS, AMH is typically elevated, reflecting the high number of small arrested follicles. AMH is now formally accepted as an alternative to ultrasound for assessing polycystic ovarian morphology. This means that for many people, a blood test alone can support this third criterion, without the need for an internal transvaginal scan. Can AMH diagnose PMOS (PCOS)? AMH can help […]

If you’ve recently heard the term PMOS and wondered what it means, or if you’ve had a PCOS diagnosis for years and want to understand what’s changed, this is your complete guide. PMOS stands for polyendocrine metabolic ovarian syndrome. It’s the new name for what was previously called polycystic ovary syndrome (PCOS). The name has changed, but the condition hasn’t, and understanding it properly has never mattered more. PMOS affects an estimated 1 in 8 women and people with ovaries worldwide, more than 3.1 million in the UK alone. Despite being one of the most common hormonal conditions, it remains widely misdiagnosed, misunderstood, and undertreated. On average, it takes two years and multiple doctor visits to get a diagnosis. You deserve better than that. This guide covers everything: what PMOS actually is, what causes it, what it feels like, how it’s diagnosed, and what you can do about it. Quick facts: What is PMOS? P – PolyendocrineM – MetabolicO – OvarianS – Syndrome Let’s break that down: Polyendocrine means more than one hormone system may be involved. PMOS can affect reproductive hormones such as testosterone, LH and FSH, but it may also affect insulin, thyroid hormones, cortisol and other metabolic pathways. Metabolic refers to the way your body processes energy, sugar and insulin. Many people with PCOS/PMOS have some degree of insulin resistance, where the body has to produce more insulin to keep blood sugar stable. Ovarian reflects the fact that the ovaries may be affected, particularly ovulation. However, despite the old name “polycystic ovary syndrome”, you do not need to have cysts on your ovaries to have the condition. Syndrome means it is a collection of features that can look different from person to person. PMOS is the most common cause of irregular periods and ovulatory infertility in people with ovaries. It is also linked to an increased risk of developing insulin resistance and longer-term health risks including type 2 diabetes, cardiovascular disease, endometrial cancer, anxiety and depression. Is PMOS the same as PCOS? PMOS is just the newer name being used for PCOS. For years, the condition was called polycystic ovary syndrome (PCOS), but that name has always been a bit misleading. Not everyone with PCOS has polycystic-looking ovaries, and not everyone with polycystic-looking ovaries has PCOS. The condition also affects far more than the ovaries. The shift towards PMOS aims to better reflect the full-body nature of the condition, including its links with insulin resistance, androgen excess, metabolic health, cardiovascular risk, mental health and fertility. That said, PCOS is still the most widely recognised search term, and most NHS, NICE and clinical guidance currently still uses PCOS. So, for now, you may see both terms used: PCOS = the older, widely used namePMOS = the newer, more accurate name You can read more about why PCOS was renamed PMOS here. What causes PMOS? The exact cause of PMOS isn’t fully understood, but research points to a combination of genetic, hormonal and metabolic factors. It tends to run in families, and if your mother, sister or aunt has PMOS, you might be at a higher risk. At its core, PMOS involves a dysfunction in the way the body produces and responds to hormones, particularly androgens and insulin. Androgen excess – the ovaries (and in some cases the adrenal glands) produce higher levels of androgens than normal. Androgens are often called “male hormones,” but they play important roles in everyone’s body. In PMOS, elevated androgens disrupt the normal development of follicles in the ovaries, preventing regular ovulation. Insulin resistance – the majority of people with PMOS have some degree of insulin resistance, meaning their cells don’t respond efficiently to insulin. This causes the pancreas to produce more insulin to compensate, and elevated insulin in turn stimulates the ovaries to produce more androgens, creating a self-reinforcing cycle. Disrupted pituitary signalling – the hormonal signals from the brain to the ovaries are altered in PMOS. LH (luteinising hormone) is often disproportionately elevated relative to FSH (follicle-stimulating hormone), which further disrupts follicle development and ovulation. Genetic factors – PMOS can run in families, suggesting genes play an important role. Researchers are trying to identify which genes are involved, but because it’s a complex condition, it’s not surprising that it’s not a single gene, but that many genes are involved. What are the symptoms of PMOS? PMOS presents differently  from person to person. Some people have many symptoms; others have very few. Some symptoms are visible; others are internal. This variability is one of the reasons it takes so long to diagnose. Irregular or absent periods Irregular menstrual cycles are one of the hallmark features of PMOS. Because elevated androgens interfere with regular ovulation, periods can arrive unpredictably, sometimes weeks late, sometimes skipped altogether. Some people experience very long cycles (35 days or more); others may go several months without a period. What counts as irregular? Cycles shorter than 21 days or longer than 35 days, fewer than 8 periods per year, or periods that have no predictable pattern. If your periods have always been irregular  or if they became irregular after stopping the pill, PMOS is one of the first things worth looking into. Hormonal acne Hormonal acne is one of the most common and most distressing symptoms of PMOS. PMOS-related acne typically appears along the jawline, chin and lower cheeks. It may flare around the time of a period, or it may be persistent and seemingly random. It tends to involve deeper, more inflamed spots rather than surface-level break out, and it often doesn’t respond well to standard skincare. If you’ve tried everything on your skin and still can’t get it under control, your hormones are worth investigating. Unwanted hair growth (hirsutism) Elevated testosterone stimulates hair growth in areas where most women don’t typically grow coarse hair, the upper lip, chin, jaw, chest, stomach and inner thighs. This is called hirsutism, and it affects a significant proportion of people with PMOS. It can range from fine, barely noticeable hair to […]

You’ve just received your hormone test results. There are numbers, units, and a column of figures labelled ” hormone reference range” and it’s not immediately obvious what any of it means, or whether you should be worried. You’re not alone. Hormone reference ranges are one of the most misunderstood parts of any blood test result. At Hertility, we interpret your hormone results in clinical context, not just against a number. This guide explains what reference ranges actually are, why they vary, and how to read your results properly. Quick summary What is a hormone reference range? When you receive hormone test results, each value is accompanied by a reference range, a set of numbers that tells you where your result sits relative to a defined population.  The first step in understanding where a reference range comes from is to remember that we expect different things from different groups of people. This can be age-related or gender-related, but can also be lifestyle-related. In actual fact, the ideal ranges are usually pretty broad and rarely take important factors such as ethnicity into account. They are usually defined by the population to which the range will apply (in this case women), but also their age. A large number of individuals from a group who are thought to represent a “normal” population, will be tested for a particular laboratory test. The reference range is then derived mathematically by taking the average value for the group and allowing for natural variation around that value (plus or minus 2 standard deviations from the average). In this way, ranges quoted by labs will represent the values found in 95% of individuals in the chosen ‘reference’ group. In other words, even in a “normal” population, a test result will lie outside the reference range in 5% of cases (1 in 20).  This is precisely why the term “reference range” is preferred over “normal range” in clinical medicine. A result outside the range is not automatically abnormal. A result inside the range is not automatically healthy. The range is a reference point, a tool to aid interpretation, not a binary verdict on your health. Why do hormone reference ranges vary between labs? One of the most confusing aspects of hormone testing is that you can test at two different labs and receive two different results, and both can be correct. This happens for several reasons. Lab environment and equipment. Every laboratory uses precisely calibrated equipment and specific reagents (the chemical substances used to detect hormone levels in a blood sample). Minor differences between labs like temperature, supplier of testing materials, calibration protocols, mean that the same sample can produce slightly different numerical results when analysed in different settings. Neither lab is producing an incorrect result. They are simply measuring with different tools, against different benchmarks. Different reference populations. Each lab establishes its reference range by testing its own reference population. If Lab A and Lab B each test a group of healthy women but recruit from different populations, ages, or regions, their resulting ranges may differ, even if the underlying biology is identical. What this means in practice. If you test at one lab and retest a month later at a different lab, a change in your result may reflect the different reference populations of each lab rather than a genuine change in your hormone levels. This is why, whenever possible, it is best to retest at the same lab  and why any result should always be interpreted against the reference range of the specific lab that analysed your sample, not a generic “normal” value found online. Type of sample: Reference ranges are also different depending on the type of sample used to measure a hormone. Take oestrogen as an example. Oestrogen can be measured in blood, saliva, or urine, but the concentration of oestrogen differs significantly between each of these, and so the reference ranges are different too. This is relevant if you ever compare results from different types of tests. A blood oestrogen result and a urine oestrogen result cannot be directly compared, even if they are measuring the same hormone. The numbers will look different, the reference ranges will be different, and the clinical interpretation will differ accordingly. How hormone reference ranges are categorised by age, sex, and cycle phase Because different groups of people have different hormone levels for entirely normal physiological reasons, reference ranges are not one-size-fits-all. They are adjusted for the characteristics of the population being assessed. By sex Testosterone is a clear example. Men have significantly higher testosterone levels than women, so separate reference ranges exist for each sex. Applying a male testosterone reference range to a female result or vice versa  would make most healthy women appear deficient. By age Many reproductive hormones change significantly across a woman’s lifespan. AMH (anti-Müllerian hormone), which reflects ovarian reserve, naturally declines with age. It would be clinically meaningless to compare a 22-year-old’s AMH to a 42-year-old’s using the same reference range, the 22-year-old would almost always appear to have “better” results simply because of age, not because of any meaningful difference in health status. At Hertility, we use age-stratified reference ranges for AMH and other hormones that change across the reproductive lifespan. This means your result is compared to the expected range for people your age, giving you a more accurate and clinically meaningful interpretation. By cycle phase Cycling hormones like FSH, LH, oestradiol, and progesterone fluctuate significantly throughout the menstrual cycle. Their reference ranges are therefore tied to a specific phase of the cycle. FSH, LH and oestradiol, for example, are typically measured on day 2 or 3 of the menstrual cycle, because the reference ranges for these hormones are calculated on day 3 of a healthy population’s cycle. Testing FSH on day 14 (mid-cycle, around ovulation) and comparing it against a day 3 reference range would produce a meaningless result because LH surges dramatically at ovulation, and FSH also rises. The timing of the test and the timing of the reference […]

Menopause support at work is an increasingly important part of employee wellbeing, inclusion, and retention. For UK employers, effective support can help reduce avoidable barriers to performance, improve employee experience, and create a more inclusive workplace for people at different life stages. This focus has been further sharpened by the government’s rollout of The Renewed Women’s Health Strategy for England. Aligned with the Employment Rights Act, the updated strategy brings a heavy focus on keeping women in the workforce by tackling health-related economic inactivity. Crucially, from Spring 2026, large employers (250+ employees) are being actively encouraged to publish voluntary “Menopause Action Plans” outlining how they support staff, a framework expected to become mandatory by 2027. To champion these changes, the government also expanded the national remit by appointing a new Women’s Employment Ambassador to ensure businesses actively dismantle workplace health barriers. The most effective menopause support combines clear policies, flexible working, practical workplace adjustments, manager training, and access to specialist health support. Together, these measures can help employees manage symptoms such as poor sleep, anxiety, hot flushes, heavy periods, fatigue, and difficulty concentrating. Why menopause support matters for UK employers Menopause can affect employees in different ways and to different degrees. For some, symptoms are manageable. For others, they can have a substantial impact on confidence, attendance, comfort, and work performance. In the UK, employers should also be aware that menopause symptoms may overlap with legal obligations under equality and health and safety frameworks. Guidance from the Equality and Human Rights Commission has made clear that if menopause symptoms have a substantial and long-term adverse effect on a person’s ability to carry out normal day-to-day activities, employers may have a duty to make reasonable adjustments. There is also growing public and employer focus on the role menopause can play in retention, progression, and the gender pay gap. Without the right support, organisations risk losing experienced employees at a point in their careers when they often hold significant knowledge, leadership capability, and commercial value. What menopause workplace benefits should UK employers offer? The most effective menopause workplace benefits are practical, consistent, and easy to access. In most organisations, support falls into five areas: Flexible working arrangements Menopause-friendly workplace adjustments Clear absence and leave guidance Manager training and internal support Access to specialist health benefits 1. Flexible working and leave policies Flexible working is one of the most important tools employers can use to support employees experiencing menopause symptoms. Symptoms can fluctuate from day to day, and rigid schedules may make work more difficult to manage. UK employers can support employees by offering: flexible start and finish times hybrid or remote working where appropriate temporary adjustments to working hours additional short breaks during the day flexibility during periods of more severe symptoms Clear menopause-related absence guidance is also important. Acas recommends that when someone is off sick because of menopause, employers should consider recording this separately from other types of sickness absence. This can help reduce the risk of employees being unfairly penalised under standard absence trigger processes. A supportive policy should make it easier for employees to ask for help without feeling that their symptoms will be treated as a performance or conduct issue. 2. Workplace adjustments that improve comfort Small adjustments to the physical working environment can make a meaningful difference to how manageable symptoms feel during the working day. In many cases, these are low-cost changes that are simple to put in place. Examples of workplace adjustments for menopause include: desk fans or improved ventilation seating near windows or cooler areas access to drinking water easy access to washrooms provision of emergency sanitary products quiet rooms or rest areas for short breaks flexibility around uniforms or dress codes to allow breathable fabrics These measures can help employees manage symptoms such as hot flushes, dizziness, fatigue, anxiety, and, for those in peri-menopause, heavy or irregular periods with greater comfort and dignity. 3. Health benefits that support menopause care In addition to practical workplace adjustments, many UK employers are strengthening their health benefits to include menopause-specific support. This can help employees access timely information, specialist guidance, and appropriate clinical care. Menopause-related employee health benefits include: occupational health referrals menopause specialist consultations counselling or mental health support nutrition support hormone health education guidance on treatment options, including HRT where appropriate Some employers also provide educational workshops or lunch-and-learn sessions to improve awareness across the wider organisation. These sessions can help colleagues and managers better understand menopause symptoms, treatment pathways, and the impact symptoms can have at work. 4. Manager training and internal support A menopause policy is only effective if managers know how to apply it. Manager confidence plays a major role in whether support is experienced as meaningful in practice. Training should help managers: have sensitive and confidential conversations respond appropriately to disclosures about symptoms understand that symptoms such as brain fog, poor sleep, or difficulty concentrating may be health-related avoid treating menopause-related challenges as misconduct or underperformance signpost employees to internal and external support Some employers also create internal support structures such as menopause champions, peer support groups, or wellbeing leads. These can help make support more visible and reduce stigma across the organisation. 5. What should a menopause policy include? A clear menopause policy helps create consistency across teams and gives employees confidence that support is available. For UK employers, a menopause policy may include: a statement of organisational commitment guidance for managers examples of workplace adjustments flexible working options how menopause-related absence should be handled confidentiality expectations information about employee benefits and support pathways signposting to occupational health, EAP support, or specialist providers The purpose of the policy should be to make support clear, practical, and fair, rather than dependent on individual manager discretion. Menopause workplace benefits: quick reference table Support area Example Why it helps Flexible working Later start times, hybrid work, adjusted hours Helps employees manage poor sleep, fatigue, and fluctuating symptoms Physical adjustments Fans, ventilation, rest spaces, washroom access Improves comfort and reduces disruption […]

There’s a lot of conflicting advice out there about trying to conceive and a surprising amount of it is wrong. People are told to try on day 14 (not always accurate), to lie down afterwards (not necessary), or that it should happen quickly if nothing’s wrong (not always the case). This guide cuts through the noise. It covers when in your cycle to time sex for the best chance of conceiving, how conception odds actually work, what might be affecting your chances, and importantly, what to do when things aren’t going as planned. Quick Facts When in the menstrual cycle are you most likely to conceive? You can only conceive during a six-day window in each menstrual cycle. This is called the fertile window, and it consists of the five days leading up to ovulation plus the day of ovulation itself. Outside of this window, the chances of pregnancy from unprotected sex is very low This window exists because of how long sperm and eggs survive in the body. Once released, an egg lives for just 12–24 hours. Sperm, on the other hand, can survive in the female reproductive tract for up to five days. That means sex in the days before ovulation can still result in conception, the sperm are already waiting when the egg arrives. When does ovulation happen? Ovulation doesn’t always happen on day 14. This is one of the most widespread and consequential misconceptions in fertility. Day 14 only applies to a textbook 28-day cycle. Latest research shows that ovulation actually occurs approximately between day 12 to 16 days for most people which means: If your cycles are irregular, ovulation timing can shift considerably from month to month. Using day 14 as your anchor when your cycle doesn’t conform to that pattern is one of the most common reasons people miss their fertile window. Hertility’s own research based on data from over 97,000 women actively trying to conceive, found that more than 41% could not accurately identify their fertile window, making this the single most common correctable barrier to natural conception. What are the chances of getting pregnant during the fertile window? The odds of conception are not equal across all six days of the fertile window, they build as you approach ovulation and peak just before the egg is released. Research shows that the two to three days immediately before ovulation carry the highest probability of conception. sex on the day of ovulation is less effective than the day before. Waiting until you’ve confirmed ovulation has occurred may mean you’ve already passed the peak window. This is why covering the full window matters, rather than pinpointing a single “best day.” How do you know when you’re ovulating? To make the most of your fertile window, you need to know when ovulation is approaching. There are several ways to identify it. The most reliable real-time indicator is a positive LH test (ovulation predictor kit), which typically detects the LH surge 24–36 hours before ovulation.  A positive test is your cue to prioritise sex in the next one to two days. They’re the most accurate day-to-day predictor available over the counter. One caveat: if you have PCOS, elevated LH throughout the cycle can produce false positives – see our PCOS and TTC guide for more on this. Egg-white cervical mucus, clear, slippery, and stretchy is another strong sign that ovulation is approaching. Basal body temperature (BBT) rises slightly after ovulation due to rising progesterone. The limitation is that this confirms ovulation has already happened, so it’s more useful for understanding your cycle pattern over time than for timing sex in the moment. Day 21 progesterone blood test A blood test measuring progesterone around day 21 of a 28-day cycle (or 7 days after suspected ovulation on other cycle lengths) can confirm whether ovulation has taken place. If your result is low or borderline, it may indicate that ovulation didn’t occur that cycle or that the timing of the test missed the progesterone peak.  Cycle tracking apps estimate your fertile window from past cycle data, a reasonable starting point for people with regular, predictable cycles, but they’re predictions, not measurements. They don’t account for cycle-to-cycle variation, stress, illness, or travel. Treat them as a guide, not a guarantee. For a full comparison of all methods, including their reliability and what works best for different cycle types, see: How to detect ovulation. Should you time sex around ovulation to increase chances of conceiving? Not necessarily, and for many couples, trying to time sex precisely creates more stress than it solves. The current clinical recommendation from NICE is sex every 2–3 days throughout the cycle. This ensures viable sperm are consistently present, without the need to nail down your ovulation date precisely. It also removes the pressure of “we have to do it tonight“, which, for many couples, is easier on the relationship and the sex itself. Something that often goes unsaid in clinical guides is that trying to conceive can make sex feel like a task. Scheduled, clinical, performance-driven. Timed sex can be hard on relationships, and the longer it goes on, the harder it gets. Something often left unsaid is that trying to conceive can make sex feel like a task. When the approach of a fertile window feels like a countdown, and sex begins to feel like a performance, that affects intimacy. It’s normal and it’s worth acknowledging. Timed sex doesn’t have to mean joyless sex, but if TTC is creating real tension around intimacy, that’s worth talking about, with your partner, and if it persists, with a professional. For some people, there are physical factors that make sex difficult or painful, including conditions like endometriosis, vaginismus, or vulvodynia. These conditions are underdiagnosed and often poorly supported, but they are treatable. If sex is painful, irregular, or difficult, this is not something to push through silently, it’s information worth sharing with a clinician, because it can be investigated and addressed. Should you only have sex on […]

If you have been diagnosed with PCOS or suspect you have PMOS, you might have seen the news this week. On 12 May 2026, a landmark paper published in The Lancet officially renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome, or PMOS. It’s one letter different in the acronym. But the reasoning behind it, and what it means for diagnosis, treatment and the millions of people living with this condition, is significant. Here’s everything you need to know. Why has PCOS been renamed? The short answer: because the old name was wrong and that had real consequences. “Polycystic ovary syndrome” implies the condition is defined by cysts on the ovaries. In reality, those are not actually pathological ovarian cysts. What is visible on ultrasound are small antral follicles – immature follicles that haven’t developed properly, not cysts in the clinical sense. Describing the condition by a feature it doesn’t actually have has caused confusion among patients and clinicians alike for decades. More importantly, the old name obscured what PCOS actually is: a complex, whole-body hormonal and metabolic condition that affects far more than the ovaries. The new name recognises that the condition is not  primarily a gynaecological disorder, but instead a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological and psychological health. The name PCOS is misleading – it focuses on ‘cysts’ and the ovaries, when the condition is much more complex than that. This has led to missed diagnoses and people not getting the right treatment. For an estimated 1 in 8 women worldwide – over 170 million people – that’s not a semantic issue, it’s a healthcare one. What does PMOS stand for and what does it mean? PMOS: Polyendocrine Metabolic Ovarian Syndrome Each word in the new name is deliberate: Polyendocrine – reflects that this is fundamentally a hormonal condition, involving multiple endocrine disruptions. People with PMOS have a disturbance in the endocrine (or chemical messenger) system of the body, which can lead to widespread impacts. This includes abnormalities in androgen production, insulin signalling, ovarian hormone regulation and neuroendocrine function. Metabolic – acknowledges the significant metabolic dimension of the condition, including insulin resistance, diabetes risk and cardiovascular risk. For many people with PMOS, the metabolic features are as impactful or more so than the reproductive ones. Ovarian – retained in the new name because the ovaries remain central to understanding the condition. Abnormalities in follicle development and ovulation are all key features of PMOS. The ovary is involved, it’s just not the only thing going on, and it’s not cysts that define it. Syndrome – correctly reflects that this is a cluster of features, not a single-cause disease. How did changing PCOS to PMOS happen? This wasn’t a quick decision. The name change followed more than a decade of vigorous debate and the most robust disease-renaming process in history. The process was led by Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research & Implementation, alongside the International Androgen Excess and PCOS Society, 56 patient and professional organisations including Verity PCOS UK  and garnered more than 22,000 survey responses from patients and multidisciplinary health professionals across all world regions. The revised name was introduced in a paper published in The Lancet and presented at the European Congress of Endocrinology in Prague. “It is fantastic that the new name now leads with hormones and recognises the metabolic dimension of the condition.” – Rachel Morman, Chair of Verity PCOS UK How is PMOS diagnosed? Nothing about the diagnostic criteria has fundamentally changed. If you were diagnosed with PCOS, that diagnosis still stands. The condition is the same, the name is what’s changing. To receive a PMOS/ PCOS diagnosis, a person must meet at least two of the following three criteria: 1. Irregular or absent menstrual cycles. Irregular cycles indicate that ovulation is not occurring regularly, a key feature of PMOS/ PCOS. According to the 2023 International Evidence-Based PCOS Guidelines, irregular cycles are defined as fewer than eight cycles per year, or cycle intervals outside the 21–35 day range, in women who are at least three years post-menarche (which is your first period). 2. Clinical or biochemical signs of high androgens (hyperandrogenism). This means either physical symptoms associated with elevated androgens such as excess facial or body hair (hirsutism), acne, scalp hair thinning or elevated androgen levels on a blood test – typically testosterone.  3. Polycystic ovarian morphology (PCOM). This refers to the appearance of the ovaries on an ultrasound scan, specifically a high number of small antral follicles (the immature follicles that house eggs) in one or both ovaries, or an increased ovarian volume. Alternatively, a high AMH (anti-Müllerian hormone) level on a blood test can be used as a marker of PCOM when an ultrasound isn’t available or appropriate. Crucially, “60% of women with the condition only need those first two – they don’t need the ovaries assessed in any way,” says Professor Teede. “For the other 30–40%, they can either have a blood test or an ultrasound, and arguably, a blood test is actually cheaper and much more convenient than an internal ultrasound.” The conversation about your condition should broaden For too long, people with PCOS were told it was “just about your periods” or “just a fertility issue.” The new name makes explicit that PMOS involves the endocrine system, metabolism, skin, mental health and cardiovascular health, not just the ovaries and reproductive function. “Language matters in medicine. The previous name often led to misconceptions and stigma, particularly around fertility. This change helps shift the conversation toward overall health rather than a single aspect of the condition.” – Dr Melanie Cree What actually causes PMOS and what does it affect? The name change is an opportunity to understand PMOS more completely. It’s not a condition that starts and ends with your cycle. Hormonal disruption (the “polyendocrine” part) PMOS involves elevated androgens like testosterone which can disrupt ovulation, cause acne, trigger unwanted hair growth (hirsutism) and contribute to hair thinning. The androgen […]

Anti-Mullerian Hormone (AMH) is one of the most talked-about markers in reproductive health, providing an insight into your hormonal health and ovarian reserve. But receiving a “low” AMH result can feel alarming, especially when you’re not sure what it actually means. The good news is that a low AMH is not a confirmation that you cannot conceive naturally. In this article, we explore what it means to have a low or out-of-range AMH result, what causes it, and what your options are; whether you’re trying to conceive now, or simply planning for the future. If you haven’t yet tested your AMH, our Advanced At-Home Hormone & Fertility Test can measure AMH alongside up to nine other key hormones, giving you a personalised, clinically meaningful picture of your reproductive health. Quick Facts: A low AMH result indicates a lower-than-expected ovarian reserve for your age, but does not mean you cannot conceive naturally AMH measures egg quantity only, it tells you nothing about egg quality, which is one of the most important factors in conception AMH naturally declines throughout life; a low result does not mean you have done anything to cause it. Certain factors, including hormonal contraception and some medical conditions can temporarily affect AMH levels. Low AMH may have implications for IVF planning and NHS eligibility, but a low result does not close the door on treatment Your AMH result should never be interpreted in isolation, it only makes sense alongside your age, other hormones, and clinical history What is AMH and what does it measure? Anti-Müllerian hormone (AMH)  is a hormone made by small fluid-filled sacs in the ovaries called follicles, each of which contains an immature egg. Because AMH is made by these follicles, your AMH level gives an indication of how many eggs you have remaining at a given time. This is known as your ovarian reserve. Unlike hormones such as FSH, oestradiol, and LH, which fluctuate significantly across the menstrual cycle, AMH remains relatively stable. This stability is one of the key reasons it became widely adopted in reproductive medicine: it can be measured on any day of your cycle and still give a meaningful result. It is worth noting, however, that more recent studies have shown that there may be some slight variation in AMH levels across the menstrual cycle, but this variation remains considerably smaller than that seen in other reproductive hormones. As a result AMH is still considered one of the most stable and reliable markers of ovarian reserve. AMH is now routinely used when someone is considering undergoing a fertility treatment to estimate how the ovaries are likely to respond to stimulation, guide medication dosage, and determine eligibility for treatment. For a deeper dive into everything AMH testing can and can’t tell you, including its role in identifying PCOS and guiding fertility treatment, read our full guide: What Does AMH Testing Tell You? 5 Key Insights About Your Fertility What Does “Low AMH” Actually Mean? When we refer to “low AMH,” we mean a result that falls below the expected range for your age group. Because AMH naturally declines as you get older, what counts as “low” is always interpreted relative to age-specific reference ranges, not a single universal cutoff. A low AMH result can suggest that your ovarian reserve may be lower than expected for someone your age. This is sometimes referred to as having a Diminished Ovarian Reserve (DOR). However, it is important to emphasise that a lower ovarian reserve does not automatically mean reduced fertility or an inability to conceive naturally. The most important thing to understand: AMH measures quantity, not quality This distinction is worth repeating, because it is the most common source of confusion and unnecessary distress after receiving a low AMH result. AMH tells you about egg quantity. It does not tell you anything about egg quality. Egg quality i.e. how healthy eggs are, how likely they are to be fertilised, and how likely they are to develop into a viable embryo is influenced primarily by age and genetics. Currently there is no reliable way to measure it directly outside of accessing embryos created during IVF. This matters enormously in practice. Research consistently shows that AMH levels alone are not strongly predictive of natural pregnancy rates. People with low AMH conceive naturally every day. Conversely, a normal or high AMH result does not guarantee fertility. Fertility is shaped by many factors: ovulation, sperm health, Fallopian tube function, uterine health, and overall wellbeing. In short: a low AMH result is not a diagnosis of infertility. Hertility’s own research found no significant association between low AMH and risk of miscarriage or recurrent pregnancy loss, an important finding that further underscores the limitations of AMH as a standalone predictor of pregnancy outcomes. What Causes Low AMH? In most cases, there is no single identifiable “cause” of a low AMH level in the way we typically think about causes of illness. It is important to know that if you have received a low AMH result, nothing you’ve done has caused this. AMH levels follow a natural trajectory across the reproductive lifespan; it peaks in the early-to-mid twenties, and then gradually declines toward menopause. This decline is a normal part of reproductive ageing, and the rate at which it happens varies between individuals, largely due to genetics. Some factors that may be associated with lower AMH levels include: Age – the most significant driver of declining AMH Genetics – family history can influence the rate of ovarian ageing Previous ovarian surgery – procedures to remove ovarian cysts or tissue (for example endometriosis) may reduce ovarian reserve Certain autoimmune conditions – which can affect ovarian function, for example Hashimoto’s disease, rheumatoid arthritis, and Addison’s disease. Cancer treatment – some types of chemotherapy and radiotherapy are referred to as gonadotoxic (i.e. toxic to the gonads such as the ovary) which can impact the ovaries Hormonal contraception – can cause a temporary, reversible reduction in AMH levels, typically by 15% to 30% and […]

In the UK, employers can support fertility and reproductive health at work by offering early diagnostic testing, expert consultations, inclusive family-forming support, fertility leave and flexible working, and access to clinically credible care and guidance. For HR teams, this matters for more than employee wellbeing. A clear fertility and reproductive health offering can help improve inclusion, reduce stress and uncertainty for employees, and strengthen retention in a competitive talent market. One of the most important things to remember is that our reproductive and hormonal health impacts us all the way through our career, not just at single points in time. The reproductive health landscape within the workplace tends to be siloed into fertility benefits or policies. Workplaces should aim to accommodate employees from every aspect of the reproductive lifespan, from those who have gynaecological conditions, sperm testing, those who need fertility care and those approaching menopause. What are fertility and reproductive health benefits? Fertility and reproductive health benefits are employer-sponsored services that help employees better understand their reproductive health, access timely care, and navigate different paths to either parenthood, symptom management or life stage health. Crucially, this support should extend beyond family planning to include the diagnosis, support, and management of reproductive health conditions (such as PCOS or endometriosis), allowing employees to get answers for symptoms and plan for their futures with clinical confidence. These benefits can include: hormone and fertility testing consultations with clinicians or specialists Diagnosis and support for conditions such as PCOS or endometriosis egg freezing guidance financial support for fertility treatment, such as IUI or IVF support for surrogacy or other family-forming journeys fertility leave and flexible working arrangements Unlike standard private medical insurance, which may limit or exclude parts of fertility care, specialist reproductive health benefits are designed to provide more targeted, comprehensive support. Why should UK employers offer fertility and reproductive health support? A strong fertility and reproductive health policy can help employers: support employee wellbeing more effectively create a more inclusive workplace for different family-forming journeys reduce stress, absenteeism, and presenteeism improve retention during key life stages demonstrate a meaningful commitment to women’s health and health equity For many employees, reproductive health concerns begin long before fertility treatment. Earlier access to testing, answers, and specialist support can make a meaningful difference to how supported they feel at work. What should a strong employer policy include? A well-designed fertility and reproductive health policy should usually include four core elements. 1. Early fertility and reproductive health checks Many employees face long waits or limited access to investigations through standard care pathways. Offering earlier access to reproductive health testing can help employees understand symptoms sooner and make more informed decisions about their next steps. This can include support for: hormone and fertility testing ovarian reserve assessments investigations into irregular cycles or hormone imbalance early identification of conditions that may affect fertility, such as PCOS, endometriosis, or thyroid dysfunction What HR teams can do: work with clinically credible providers that offer accessible testing and clear follow-up pathways. 2. Inclusive family-forming support A modern policy should reflect the fact that there is no single route to parenthood. Support should be inclusive of employees pursuing IVF, IUI, egg freezing, donor conception, surrogacy, LGBTQ+ family-forming pathways, and single parenthood by choice. A more inclusive approach may include: financial support or stipends for treatment access to approved clinics or specialists support that is not limited to one definition of infertility language and eligibility criteria that reflect a broad range of family structures What HR teams can do: review whether current benefits are accessible and relevant for all employees, not only heterosexual couples following a traditional treatment pathway. 3. Fertility leave and flexible working Fertility treatment and reproductive health care can involve repeated appointments, physical side effects, and emotional strain. Practical workplace support matters. A supportive policy may include: paid time off for fertility-related appointments and treatment leave for partners flexible start times or remote working for clinic appointments confidential processes for requesting support What HR teams can do: make expectations clear, train managers on handling requests sensitively, and ensure employees are not forced to disclose more than necessary. 4. Access to expert guidance and onward care Testing is only useful if employees understand what their results mean and what to do next. Employer support should include access to clinicians, education, and onward referral pathways where appropriate. This might include: clinician-reviewed results specialist consultations tailored next-step guidance support for managing symptoms and understanding treatment options What is the legal position in the UK? There is currently no statutory right to paid time off for fertility treatment in the UK, but employers still need to approach fertility and reproductive health support carefully and consistently. HR teams should be aware of: Pregnancy discrimination protections under the Equality Act 2010 once an embryo has been implanted the need to treat medical appointments fairly and sensitively the wider duty to create policies and management practices that reduce the risk of unfair treatment, discrimination, or employee relations issues As expectations around fertility support continue to evolve, many employers are choosing to go beyond minimum legal requirements and introduce clearer internal policies. How can HR teams implement fertility and reproductive health support well? A policy is more effective when it is practical, visible, and easy to access. HR teams should consider: defining what support is available and who it applies to making language inclusive and easy to understand training managers to respond with sensitivity and consistency providing confidential signposting to support choosing providers with clear clinical standards and appropriate follow-up care reviewing whether support covers prevention and early insight, not only treatment Where Hertility fits Many fertility benefits focus on support once an employee is already facing treatment. Hertility takes a proactive approach by helping employees access earlier insight into their reproductive and hormone health. Hertility supports employers with a diagnostics-led model that includes: at-home hormone and fertility testing screening for identifying issues such as PCOS, endometriosis, and hormone imbalances clearer insight into reproductive health and future […]

Research shows that on average, it takes two years and visits to three different doctors for someone to get a diagnosis of polycystic ovary syndrome (PCOS), even though it’s one of the most common hormonal conditions in the UK, affecting around 1 in 10 women. Part of the problem is that PCOS presents differently in different people. There’s no single symptom that confirms it, no single test that catches every case, and whilst the  diagnostic criteria is  clinically sound, it requires ruling out other conditions before it can be applied. Add  that to the reality that many GPs have limited time and variable knowledge of reproductive hormones,  it’s not difficult to understand why so many people spend years being told their symptoms are normal, or being tested for the wrong things. This guide walks through exactly how PCOS is diagnosed: the criteria clinicians use, the tests involved, what the process typically looks like, and what you can do if you’re struggling to get answers. Quick Facts How is PCOS diagnosed? PCOS is most commonly diagnosed using what’s known as the Rotterdam criteria, established by an international consensus in 2003 and last updated in 2023. To receive a PCOS diagnosis, a person must meet at least two of the following three criteria: 1. Irregular or absent menstrual cycles. This means cycles that are consistently shorter than 21 days, longer than 35 days, or absent altogether. Irregular cycles indicate that ovulation is not occurring regularly, a key feature of PCOS. According to the 2023 International Evidence-Based PCOS Guidelines, irregular cycles are defined as fewer than eight cycles per year, or cycle intervals outside the 21–35 day range, in women who are at least three years post-menarche (which is your first period). 2. Clinical or biochemical signs of high androgens (hyperandrogenism). This means either physical symptoms associated with elevated androgens such as excess facial or body hair (hirsutism), acne, or scalp hair thinning or elevated androgen levels on a blood test – typically testosterone. Importantly, you don’t need both signs of hyperangrogenism – physical signs alone, or blood results alone, can satisfy this criterion. 3. Polycystic ovarian morphology (PCOM). This refers to the appearance of the ovaries on an ultrasound scan, specifically a high number of small antral follicles (the immature follicles that house eggs) in one or both ovaries, or an increased ovarian volume. Alternatively, a high AMH (anti-Müllerian hormone) level on a blood test can be used as a marker of PCOM when an ultrasound isn’t available or appropriate. Two out of three. That’s the threshold. Which means you can have PCOS without polycystic-looking ovaries on a scan. You can have PCOS without acne or excess hair growth. You can have PCOS with a relatively regular period. This variability is one reason why the diagnosis of PCOS is frequently missed or delayed – there’s no single presentation that fits everyone. What tests might I need to do to get a PCOS diagnosis? A PCOS diagnosis is built from a combination of clinical assessments, blood tests, and often an ultrasound. Here’s what each one involves. Blood tests for PCOS diagnosis Blood tests are central to PCOS diagnosis, both for assessing hormone levels and for ruling out other conditions that can mimic PCOS. The following are typically included in a diagnostic workup: LH and FSH Luteinising hormone (LH) and follicle-stimulating hormone (FSH) are both made by the pituitary gland and work together to regulate the menstrual cycle. In PCOS, LH is often elevated relative to FSH, producing a raised LH:FSH ratio (typically greater than 2:1). This is one of the hormonal patterns clinicians look for in the early follicular phase, ideally tested around day 2–5 of the cycle. Oestradiol Oestradiol (the primary form of oestrogen) is tested alongside FSH to interpret the hormonal picture correctly. High oestradiol can suppress FSH artificially, which is why these two should always be read together. Testosterone and other androgens Testosterone and DHEAS (dehydroepiandrosterone sulphate) are tested to assess androgen levels. Elevated androgens support the hyperandrogenism criterion and help explain symptoms like excess body or facial hair and acne.  SHBG blood test measures the level of a protein called sex hormone binding globulin (SHBG) in your blood. SHBG attaches to sex hormones such as testosterone and estrogen and helps control how much of these hormones are active  in the tissues of your body and to understand how testosterone and oestrogen are working in the body. AMH (anti-Müllerian hormone) AMH is made by the antral follicles in the ovaries (early stage follicles that haven’t been selected for ovulation yet) and reflects the size of your egg reserve. In PCOS, AMH is often significantly elevated becausethere is a high number of small follicles stuck at different stages of development. A high AMH can serve as a marker of polycystic ovarian morphology in clinical settings, particularly when an ultrasound is unavailable. AMH doesn’t fluctuate dramatically across the cycle but is ideally tested on day 3 of the cycle for consistency. Thyroid function tests (TSH and free T4) Both an underactive and overactive thyroid can cause irregular cycles, weight changes, and fatigue that closely resemble PCOS symptoms. Ruling out thyroid issues is a standard part of the diagnostic process. Prolactin Elevated prolactin (hyperprolactinaemia) can also disrupt the menstrual cycle and cause irregular or absent periods. Testing prolactin helps exclude this as an alternative explanation for cycle irregularity. Glucose and insulin / HbA1c Because insulin resistance affects a lot of people with PCOS and significantly impacts its management, assessing metabolic markers such as fasting glucose or HbA1c is an important part of a thorough diagnostic workup. These tests are ideally taken in the early follicular phase, between days 2–5 of the menstrual cycle, when cycling hormones like LH, FSH, and oestradiol are at their baseline. If your cycles are very irregular, your doctor may advise testing at a specific point or to simply proceed whenever possible. Hertility’s Advanced At-home Hormone & Fertility Test checks for these markers including LH, FSH, oestradiol, testosterone, […]

In our recent webinar, we unpacked the science behind fertility, explaining how hormones regulate ovulation, why timing matters, and how ovarian reserve naturally changes with age. We explored evidence-based ways to optimise egg and sperm health through nutrition, sleep, stress management, and reducing exposure to endocrine disruptors. But as always, the most important part of the session was your questions. Many of them couldn’t be answered fully in the time we had live. So we’re starting something new. Welcome to the Hertility Expert Q&A series,  a new post-webinar blog series where our clinical and research team answer your most pressing women’s health questions in depth. This edition covers the questions submitted during our fertility science webinar, including: This edition’s questions were answered by Emily Moreton, Clinical Services Manager at Hertility, fertility nurse, and registered nutritionist specialising in reproductive health. Emily holds a Master’s degree in Clinical Nutrition and Public Health from UCL and is a trained nutrition counsellor. Her work focuses on health-promoting behaviours, empowering individuals to improve their relationship with food, movement, and their body without restrictive dieting. ​​Her clinical expertise supports individuals in optimising fertility, managing PCOS and hormonal symptoms, maintaining a healthy pregnancy, and navigating menopause with confidence. We’ve rounded up every answer here so nothing gets lost in your inbox. Folic acid vs methylfolate: what’s the difference and which should you take? If you’re trying to conceive, you’ve likely been told that folic acid is non-negotiable. But then you see supplements advertising “methylfolate” or “5-MTHF” and suddenly the choice feels far less straightforward. Here’s what you actually need to know. The basics first. Folate is the natural form of vitamin B9 found in food. Folic acid is the synthetic version used in most prenatal supplements and fortified foods. Methylfolate, also known as 5-methyltetrahydrofolate (5-MTHF)  is the biologically active form your body ultimately uses. When you take folic acid, your body converts it into methylfolate through a series of enzymatic steps. For most people, this happens efficiently. The official recommendation is . 400mcg of folic acid for all women from three months before conception through the first 12 weeks of pregnancy to reduce the risk of neural tube defects (NTDs) like spinal bifida. This recommendation is backed by major health bodies including the NHS and CDC, and is supported by decades of large-scale clinical trial data. Folic acid is currently the only form of folate clinically proven in human trials to significantly reduce NTD risk. So why does methylfolate exist as an alternative? Some people carry variations in a gene called MTHFR, which can reduce how effectively the body converts folic acid into its active form. For those individuals, methylfolate may raise blood folate levels more efficiently because it bypasses this conversion step entirely. The catch is that methylfolate has not been put through the same rigorous, large-scale trials as folic acid for NTD prevention and at this point, it would be unethical to design such a trial, because it would require withholding a known protective intervention from pregnant women.  Which is better absorbed: Folic Acid or Methylfolate? Folic acid is actually very well absorbed, and crucially it is the form used in the large clinical trials that proved it prevents neural tube defects like spina bifida. That is why public health bodies, including the NHS, recommend 400 micrograms of folic acid daily before conception and during the first trimester. However, this dose needs to be increased to 5 milligrams daily (prescription-only in the UK) in certain higher-risk situations. When is a higher 5mg dose of Folic Acid recommended? A higher 5mg dose (prescription-only in the UK) may be recommended if you: When might methylfolate be worth considering?  It may be appropriate in cases of known MTHFR variants, recurrent pregnancy loss, recurrent implantation failure, or where a previous pregnancy was affected by a neural tube defect despite folic acid supplementation. Hertility’s in-house clinical team or registered nutritionists and dieticians if you’d like some advice but ultimately it should be up to the individual to make an informed decision. A large number of fertility supplements now use methylfolate rather than folic acid and that shift isn’t without reason. The reality is that experts are divided. Folic acid remains the gold standard in public health guidelines because it’s backed by decades of clinical trial data. Methylfolate is a promising and increasingly popular alternative, but it doesn’t yet carry the same evidence base for preventing neural tube defects in large-scale trials.  Which foods are richest in folate? Supplementation is important, but dietary sources matter too. Good sources include spinach, kale, Brussels sprouts, broccoli, beans and lentils, eggs, oranges, fortified breakfast cereals, nuts and seeds, and wholegrains. Because folate is water-soluble and lost during cooking, steaming or microwaving vegetables rather than boiling helps preserve it. The bottom line: for most women, folic acid remains the evidence-backed standard. If you have reason to believe methylfolate may be more appropriate for you, whether due to a genetic variant or a history of pregnancy complications, speak with your GP or Hertility’s clinical team before switching. What is the best nutrition approach for PCOS and improving ovulation? PCOS is one of the most common hormonal conditions affecting women of reproductive age and one of the most common causes of irregular ovulation. Search online for the “best diet for PCOS fertility”  or “how to improve ovulation naturally with PCOS,”  and you’ll be met with extremes: cut carbs, go keto, eliminate gluten, try fasting. The evidence doesn’t support most of it. There is no single recommended PCOS diet. The goal of nutrition in PCOS is not restriction, it’s choosing foods that stabilise blood sugar and reduce inflammation, consistently, over time. Understanding the link between PCOS and insulin. At its core, PCOS is often linked to insulin resistance. When insulin levels stay elevated, the ovaries produce more androgens such as testosterone, which can interfere with follicle development and regular ovulation. Managing insulin through diet is therefore one of the most evidence-based nutritional targets in PCOS. A Mediterranean-style […]